Search
Leronlimab
go.drugbank.com/drugs/DB05941InvestigationalLeronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn.[L12684] It was first described in the literature in 2001. … [A3922] This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.[A192846,A192858,L12684]
Magnesium ascorbate
go.drugbank.com/drugs/DB14484ApprovedNutraceuticalCategories: Compounds used in a research, industrial, or household settingR112
go.drugbank.com/drugs/DB06252ExperimentalR112 is an investigational compound developed to treat Allergic Rhinitis. It's mechanism of action is to inhibit SYK kinase.
Gabexate
go.drugbank.com/drugs/DB12831InvestigationalGabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. … Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]
Glisoxepide
go.drugbank.com/drugs/DB01289InvestigationalHowever it inhibits taurocholate uptake only in the absence of sodium ions. … Glisoxepide is one of the sulphonamide-derived oral antidiabetic drugs. It inhibits the uptake of bile acids into isolated rat hepatocytes.
Categories: Drugs Used in DiabetesOBE101
go.drugbank.com/drugs/DB05080ExperimentalObecure is repurposing betahistine, which is an H1 receptor agonist and partial H3 receptor antagonist for the treatment of obese individuals and for other weight management indications. … OBE101 is a new weight loss drug developed by Obecure Ltd. It is a new formulation that is based on the vertigo medication, Betahistine.
QR-333
go.drugbank.com/drugs/DB05533Investigationalthat can lead to numbness, skin ulcers, constant pain or extreme sensitivity to a stimulus. … QR-333 is a concentrated and standardized nutrient based active compounds dosed in a topical cream designed to reduce oxidative stress and treat symptoms of Diabetic Peripheral Neuropathy, a nerve disorder
EMZ702
go.drugbank.com/drugs/DB05021InvestigationalEMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.
HSV-2 theracine
go.drugbank.com/drugs/DB05811ExperimentalHSV-2 theracine is an attenuated recombinant vaccine developed by AuRx for the treatment of genital herpes.
Idraparinux
go.drugbank.com/drugs/DB06406InvestigationalIdraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events.